SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company that develops and markets specialty products for allergies, opioid overdoses, respiratory and inflammatory diseases, announced today that it is hosting an investor conference Call on Monday, November 22, 2021 at 2:00 p.m. Pacific Time to discuss financial and operating results for the first nine months of 2021 and to provide a business update. The company’s financial results press release will be available after 1:00 p.m. Pacific Time on November 22, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021 on that date.
Event: Conference Call on Adamis Pharmaceuticals Financial Results
Date: Monday, November 22, 2021
Time: 14:00 PT (17:00 ET)
US Dial-Up Toll Free: 1-877-423-9813
Toll-based / international dial-in: 1-201-689-8573
Conference ID: 13725311
Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host the conference call along with other members of the management team. The call is public and informs of recent developments, events that have occurred during the year, and specific goals for future periods. During the conference call, forward-looking statements may be made about expectations regarding future company performance.
A live audio webcast of the conference call will also be available through this link – https://viavid.webcasts.com/starthere.jsp?ei=1515468&tp_key=857fdc0361, with a replay shortly after the live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on the development and commercialization of products in various therapeutic areas, including allergies, opioid overdoses, respiratory and inflammatory diseases. The company’s SYMJEPI (epinephrine) injection products are FDA approved for the emergency treatment of acute allergic reactions, including anaphylaxis. The company’s injection product ZIMHI (naloxone) is approved for the treatment of opioid overdose. Tempol is under development to treat patients with COVID-19 and a phase 2/3 clinical trial is ongoing. For more information about Adamis Pharmaceuticals, please visit www.adamispharmaceuticals.com and follow us on Twitter and LinkedIn.
Adamis Investor Relations